Latest Denosumab Stories

2011-09-26 11:19:05

Quality of life can be significantly improved Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher will tell the 2011 European Multidisciplinary Cancer Congress today (Sunday). Professor Stéphane Oudard, Head of the Oncology Department at the Georges Pompidou Hospital, Paris, France, says that his team's research on the effects of the monoclonal antibody...

2011-09-20 05:55:51

(Ivanhoe Newswire) — OSTORA, a new oral drug made of salmon calcitonin, was in its third phase of study to determine if it effectively treated postmenopausal osteoporosis. The researchers deemed it safe and effective. The ORACAL study was a Phase III multinational, randomized, double-blind, double-dummy, placebo-controlled trial of Tarsa's oral recombinant salmon calcitonin compared to commercially available, synthetic salmon calcitonin administered by nasal spray and to placebo. The...

2011-08-18 15:13:00

THOUSAND OAKS, Calif., Aug. 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011. "The breadth of data being...

Word of the Day
  • Color; hue; complexion.
This word is Middle English in origin.